JP2021514979A5 - - Google Patents
Info
- Publication number
- JP2021514979A5 JP2021514979A5 JP2020544853A JP2020544853A JP2021514979A5 JP 2021514979 A5 JP2021514979 A5 JP 2021514979A5 JP 2020544853 A JP2020544853 A JP 2020544853A JP 2020544853 A JP2020544853 A JP 2020544853A JP 2021514979 A5 JP2021514979 A5 JP 2021514979A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- cancer
- composition according
- item
- effective dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023195862A JP2024012649A (ja) | 2018-02-26 | 2023-11-17 | Ｃｈｋ１阻害剤を含む癌の治療方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862635459P | 2018-02-26 | 2018-02-26 | |
| US62/635,459 | 2018-02-26 | ||
| US201862650192P | 2018-03-29 | 2018-03-29 | |
| US62/650,192 | 2018-03-29 | ||
| US201862743993P | 2018-10-10 | 2018-10-10 | |
| US62/743,993 | 2018-10-10 | ||
| PCT/US2019/019643 WO2019165458A1 (en) | 2018-02-26 | 2019-02-26 | Methods of treatment of cancer comprising chk1 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023195862A Division JP2024012649A (ja) | 2018-02-26 | 2023-11-17 | Ｃｈｋ１阻害剤を含む癌の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021514979A JP2021514979A (ja) | 2021-06-17 |
| JP2021514979A5 true JP2021514979A5 (enExample) | 2022-03-04 |
Family
ID=67687903
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544853A Withdrawn JP2021514979A (ja) | 2018-02-26 | 2019-02-26 | Ｃｈｋ１阻害剤を含む癌の治療方法 |
| JP2023195862A Pending JP2024012649A (ja) | 2018-02-26 | 2023-11-17 | Ｃｈｋ１阻害剤を含む癌の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023195862A Pending JP2024012649A (ja) | 2018-02-26 | 2023-11-17 | Ｃｈｋ１阻害剤を含む癌の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200397796A1 (enExample) |
| EP (1) | EP3758678A4 (enExample) |
| JP (2) | JP2021514979A (enExample) |
| KR (1) | KR20200126388A (enExample) |
| CN (1) | CN112469391A (enExample) |
| AU (1) | AU2019224164A1 (enExample) |
| CA (1) | CA3092079A1 (enExample) |
| MX (1) | MX2020008881A (enExample) |
| WO (1) | WO2019165458A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019012176A (es) | 2017-04-10 | 2020-02-19 | Sierra Oncology Inc | Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral. |
| AU2020274164A1 (en) * | 2019-05-14 | 2021-11-25 | Sierra Oncology, Inc. | Methods of treating cancer using Chk1 inhibitors |
| CN120441567A (zh) | 2020-04-07 | 2025-08-08 | Crt先锋基金有限公司 | Chk1抑制剂的合成方法 |
| BR112023002453A2 (pt) * | 2020-08-12 | 2023-05-02 | Boundless Bio Inc | Composições de agente de via de estresse de replicação e métodos para tratar câncer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8481557B2 (en) * | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| US9345705B2 (en) * | 2011-09-15 | 2016-05-24 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| JP6027230B2 (ja) * | 2012-05-15 | 2016-11-16 | キャンサー・リサーチ・テクノロジー・リミテッド | ５−［［４−［［モルホリン−２−イル］メチルアミノ］−５−（トリフルオロメチル）−２−ピリジル］アミノ］ピラジン−２−カルボニトリルおよびその治療上の使用 |
| MX2019012176A (es) * | 2017-04-10 | 2020-02-19 | Sierra Oncology Inc | Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral. |
| AU2018278336A1 (en) * | 2017-06-01 | 2020-01-16 | Crt Pioneer Fund Lp | Biomarkers and patient selection strategies |
-
2019
- 2019-02-26 JP JP2020544853A patent/JP2021514979A/ja not_active Withdrawn
- 2019-02-26 CN CN201980018748.5A patent/CN112469391A/zh active Pending
- 2019-02-26 US US16/975,686 patent/US20200397796A1/en not_active Abandoned
- 2019-02-26 CA CA3092079A patent/CA3092079A1/en active Pending
- 2019-02-26 KR KR1020207026214A patent/KR20200126388A/ko not_active Ceased
- 2019-02-26 WO PCT/US2019/019643 patent/WO2019165458A1/en not_active Ceased
- 2019-02-26 AU AU2019224164A patent/AU2019224164A1/en not_active Abandoned
- 2019-02-26 EP EP19757456.9A patent/EP3758678A4/en not_active Withdrawn
- 2019-02-26 MX MX2020008881A patent/MX2020008881A/es unknown
-
2023
- 2023-11-17 JP JP2023195862A patent/JP2024012649A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019396895B2 (en) | Combination of antibody-drug conjugate with PARP inhibitor | |
| TW202038957A (zh) | 抗體-藥物結合物與激酶抑制劑之組合 | |
| JP2019521087A5 (enExample) | ||
| WO2021063332A1 (zh) | 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途 | |
| JP2020516693A5 (enExample) | ||
| TW202214243A (zh) | 西奧羅尼聯合免疫檢查點抑製劑在抗腫瘤治療中的應用 | |
| JP2023539589A5 (enExample) | ||
| JP2023542065A (ja) | 抗体－薬物複合物及びｃｄｋ９阻害剤の組み合わせ | |
| CN117956998A (zh) | 治疗kras突变的癌症患者 | |
| WO2023095929A1 (ja) | 悪性腫瘍治療薬 | |
| KR20240125925A (ko) | 항체-약물 콘쥬게이트와 parp1 선택적 억제제의 조합 | |
| Liu et al. | Research progress of DNA damage repair (DDR) and DDR inhibitors in tumor immunotherapy | |
| Di Maria et al. | Applying molecular hybridization to design a new class of pyrazolo [3, 4-d] pyrimidines as Src inhibitors active in hepatocellular carcinoma | |
| CN110522753A (zh) | 一种新型抗肿瘤药物组合物、制剂和应用 | |
| CN112870366B (zh) | Ezh2抑制剂在制备治疗肿瘤药物中的新用途 | |
| WO2019114785A1 (zh) | Pd-1抗体用于治疗肿瘤的用途 | |
| US20240180910A1 (en) | Method for treating cancer with a chemotherapeutic modifier | |
| CN113840608A (zh) | Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| TW201513870A (zh) | 含伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| US20220323443A1 (en) | Combination therapy for cancer treatment | |
| JP7311177B2 (ja) | Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用 | |
| WO2024118897A1 (en) | Cancer treatments using a prmt5 inhibitor and a mat2a inhibitor | |
| JP2024509920A5 (enExample) | ||
| JP2023526232A5 (enExample) | ||
| CN112870365A (zh) | Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途 |